Hereditary hemochromatosis is a condition characterized by iron overload, which is both treatable and preventable. It's mainly related to hepcidin deficiency related to mutations in genes involved in hepcidin regulation. Iron overload increases the risk of disease such as liver cirrhosis, heart disease and diabetes. Two HFE genotypes have been commonly described in cases of iron overload, C282Y homozygosity and C282Y/H63D compound heterozygoty. The diagnosis of this rare disease now can be explored by biological and imaging tools. We report a case of compound heterozygous C282Y/H63D discovered by family screening for elevated serum ferritin.
Introduction
HFE hemochromatosis is a genetic disease related to mutation in HFE gene [1] . Its prevalence in Morocco is unknown and is believed to be rare. In HFE related iron overload, 2 major genotypes have been described: C282Y homozygosity and C282Y/ H63D compound heterozygosity. The prevalence of homozygous C282Y in Caucasians is very high, about 3% -5% [2] , and the prevalence of C282Y/H63D compound heterozygosity is 4 times higher [3] . In clinical iron overload and iron overload related disease, the dominant genotype is C282Y, and a small proportion of cases are compound heterozygotes [3] . Though the clinical penetrance of C282Y homozygosity is about 28% in males and 1% in females [4] , the penetrance of compound heterozygosity is about 13.5% [5] .
It has been recently confirmed that heterozygosity is rarely clinically overt and serum ferritin is higher in this population compared with mutation free controls [6] . The pa-thophysiology is better known, and hepcidin deficiency is the main mechanism leading to iron overload [5] . The liver synthesis of hepcidin is decreased and inappropriate to iron burden in case of HFE mutation. The role of hepcidin is to insure the iron homeostasis by regulating ferroportin related intestinal absorption and excretion by the reticuloendothelial macrophages. Plasma iron overload consequent to unregulated intestinal absorption and erythrophagocytosis iron release, lead to high transferrin-iron saturation [TS] and generate a non transferrin bound iron taken by organs, mostly liver, pancreas and heart. Iron deposition in these organs leads in the ultimate stage to organ dysfunction and failure ( Figure 1 ) [7] [8]). In heterozygotes, it is not yet clear if serum ferritin (SF) level > 1000 ng/ml is isolated risk factor for disease development or associated comorbid factors are necessary [9] .
HFE-related hemochromatosis is the classical and first described form of genetic iron overload [10] . The HFE gene located on chromosome 6 codes for the membrane protein HFE, a MCH-like protein whose definite role at the membrane remains unclear [8] [11] .
The most frequent and classical mutation of this gene is the p.Cys282Tyr (C282Y) mutation. Prevalence of this mutation is high in Caucasian population (10% of the subjects are heterozygous, and 3 to 5 subjects per thousand are homozygous), but almost absent in nonwhite populations [11] . Other genotypes commonly included in HFE than C282Y homozygosity cannot explain overt iron overload and do not result in clinically significant iron overload in the absence of cofactors accounting for disturbed iron metabolism (alcoholism or metabolic syndrome): compound heterozygosity C282Y/H63D.
However, some subjects with compound heterozygosity, even without known cofactors, increased transferrin-iron saturation and serum ferritin. Other rare HFE mutations have been described associated with those frequent genotypes, thus explaining unusual cases of iron overload: type 2 HJV and HAMP, type 3 TFR2, type 4 ferroportin [11] ( Table 1 ). We report a rare case in our settings of compound heterozygosity C282Y/H63D revealed by family screening treated by phlebotomy. 
The Natural History of Disease and Clinical Expression

Observation
We report a case of a male patient 56 years old, followed for diabetes mellitus for 6 months with Hba1c within normal range under oral anti-diabetic OAD, his tobacco consumption is 800 cigarettes/year, with no alcohol abuse. His brother 61 years old has a compound heterozygous C282Y/H63D hemochromatosis managed with phlebotomy treatment every 2 weeks up to a ferritin to 56 ng/ml during a phase of attack (the initial serum ferritin 756 ng/ml), his sister and mother have diabetes mellitus. The patient was screened for HFE hemochromatosis and was referred to our unit for hyperferritinemia (1102 ng/ml). He was symptoms free and his blood tests revealed transferrin-ironsatu-ration at 65%, the blood count was normal as it was for diabetes tests, cholesterol, hemostasis, liver enzymes and renal function. Genetic testing for HFE hemochromatosis concluded to compound heterosigosity C282Y/H63D (Figure 2 ). Hepatic MRI evaluated iron overload to 230 micromol/g +/−50 (normal <36). Cardiac evaluation found no abnormality, the left ventricular ejection fraction was 62%. The patient has regular phlebotomies (he received 15 sessions of phlebotomy treatment during the attack phase every 3 weeks until a serum ferritin at 43.25 ng/ml). Currently, he is on remission with a maintenance phlebotomie every 2 -4 months), and the follow up is uneventful. Figure 2 . Genetic testing for HFE hemochromatosis concluded to compound heterosigosity C282Y/H63D.
Discussion
Due to variability in the clinical penetrance of hemochromatosis, visceral iron overload was observed in less than 10% of patients who are homozygous for the C282Y mutation, with a clinical expression in 24% to 43% among males and 1% to 14% among women (low percentage of men due to monthly menstruation resulting from a loss of iron and having a protective effect) [11] . While the compound heterozygosity (C282Y/ H63D) patients represent only 5% of the cases of hemochromatosis [11] [12] .
Knowing that heterozygosity H63D is very common in the general population about [12]- [14] .
In our case, the importance of iron overload in the body was evaluated biologically and radiologically with very high values (ferritin > 1000 ng/ml, TS 65% and major liver overload was estimated by MRI at 230 μmol/g +/− 50 (normal < 36 µmol/g) which leads us to indicate the phlebotomy treatment (the signed iterative).
Conclusions
In the literature, the weight of the C282Y/H63D genotype in the occurrence in iron overload is very relative and patients with this genotype are less frequent than expected.
They are diagnosed at an advanced age and more commonly associated with predisposing factors.
The therapeutic management of patients' compound heterozygosity (C282Y/H63D) is essentially based on the evaluation of iron overload in the body including liver MRI that is a review of reference to detect it.
